The Monoclonal Antibodies
Partnering Terms and Agreements report provides comprehensive understanding and
unprecedented access to the monoclonal antibodies partnering deals and
agreements entered into by the worlds leading healthcare companies.
The report provides a detailed
understanding and analysis of how and why companies enter monoclonal antibody
partnering deals. The majority of deals are development stage whereby the
licensee obtains a right or an option right to license the licensors monoclonal
antibody technology. These deals tend to be multicomponent, starting with
collaborative R&D, and commercialization of outcomes.
This report provides details of the
latest monoclonal antibody deals announced in the healthcare sectors.
Understanding the flexibility of a
prospective partner’s negotiated deals terms provides critical insight into the
negotiation process in terms of what you can expect to achieve during the
negotiation of terms. Whilst many smaller companies will be seeking details of
the payments clauses, the devil is in the detail in terms of how payments are
triggered – contract documents provide this insight where press releases and
databases do not.
To
Read the Complete Report with TOC Visit:
http://www.marketresearchreports.biz/analysis-details/monoclonal-antibodies-partnering-terms-and-agreements
This report contains a comprehensive
listing of all monoclonal antibody partnering deals announced since 2007
including financial terms where available including over 700 links to online
deal records of actual biomarker partnering deals as disclosed by the deal
parties. In addition, where available, records include contract documents as
submitted to the Securities Exchange Commission by companies and their
partners.
Contract documents provide the
answers to numerous questions about a prospective partner’s flexibility on a
wide range of important issues, many of which will have a significant impact on
each party’s ability to derive value from the deal.
For example, analyzing actual
company deals and agreements allows assessment of the following:
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What are the precise rights granted or optioned?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
The initial chapters of this report
provide an orientation of monoclonal antibody dealmaking and business
activities.
To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis/168863
Chapter 1 provides an introduction to the report, whilst
Chapter 2 provides an overview of the trends in monoclonal antibody
dealmaking since 2007, including details of average headline, upfront,
milestone and royalty terms.
Chapter 3 provides a review of the leading monoclonal antibody deals
since 2007. Deals are listed by headline value and most active of all biopharma
companies. Where the deal has an agreement contract published at the SEC a link
provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma
companies with a brief summary followed by a comprehensive listing of
monoclonal antibody deals as well as contract documents available in the public
domain. Where available, each deal title links via Weblink to an online version
of the actual contract document, providing easy access to each contract
document on demand.
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email: sales@marketresearchreports.biz
Website: http://www.marketresearchreports.biz/
No comments:
Post a Comment